Evidence map›Paper›PMID 29427180›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2018

Alleviation of Trigeminal Nociception Using p75 Neurotrophin Receptor Targeted Lentiviral Interference Therapy.

Valerie B O'Leary, Marie O'Connell, Inga Antyborzec, Vasilis Ntziachristos, J Oliver Dolly, Saak V Ovsepian

Open access · bronzeAbstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Valerie B O'LearyInternational Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland.
Marie O'ConnellInternational Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland.
Inga AntyborzecInternational Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland.
Vasilis NtziachristosHelmholtz Zentrum München - German Research Center for Environmental Health, Institute for Biological and Medical Imaging, Ingolstaedter Landstrasse 1, 85764, Neuherberg, Germany.
J Oliver DollyInternational Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland.
Saak V OvsepianInternational Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin 9, Ireland. saak.ovsepian@gmail.com.
Dublin City University · IEHelmholtz Zentrum München · DETechnical University of Munich · DE

Funding

Science Foundation Ireland 00023654
6 · The paper itself

Abstract

Acute and chronic trigeminal (TG) neuropathies are the cause of considerable distress, with limited treatments available at present. Nociceptive neurons enriched with the vanilloid type 1 receptor (VR1) partake in pain sensation and sensitization in the TG system. While VR1 blockers with anti-nociceptive potential are of substantial medical interest, their use remains limited due to poor selectivity and lack of cell-targeting capabilities. This study describes a methodology for the alleviation of nociception via targeted depletion of VR1 in TG sensory neurons in rats. In cultured TG ganglion neurons, VR1 expression was virtually abolished by lentiviral short hairpin RNA (LV-VR1). By decorating GFP encoding LV (LV-GFP) and LV-VR1 with IgG192 for targeting TG sensory neurons enriched with the p75 neurotrophin receptor (p75NTR), transduction of a reporter GFP and VR1 depletion was achieved after injection of targeted vectors into the whisker pad. In IgG192/LV-VR1-injected rats, the behavioral response to capsaicin exposure as well as Erk 1/2 phosphorylation and VR1 current activation by capsaicin were significantly reduced. This pioneering investigation, thus, provides a proof of principle for a means of attenuating TG nociception, revealing therapeutic potential.

Indexed as

AnimalsCapsaicinCells, CulturedFemaleLentivirusMAP Kinase Signaling SystemNerve Tissue ProteinsNociceptionRats, WistarReceptors, Growth FactorReceptors, Nerve Growth FactorRNA, Small InterferingSensory Receptor CellsTrigeminal GanglionTRPV Cation ChannelsCapsaicinNerve Tissue ProteinsNgfr protein, ratReceptors, Growth FactorReceptors, Nerve Growth FactorRNA, Small InterferingTrpv1 protein, ratTRPV Cation ChannelsCapsaicinNeuropathic painNeurotherapeuticsp75NTRTRPV1

Identifiers

PMID29427180
PMCPMC5935639
OpenAlexW2789607365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.